Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Gonococcus | Research

Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

Authors: Jiaojiao Zhong, Wenjing Le, Xuechun Li, Xiaohong Su

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

With the widespread use of antibiotics, antimicrobial resistance in Neisseria gonorrhoeae is worsening. The objective of this study was to evaluate the efficacy changes of seven antibiotics in the treatment of N. gonorrhoeae by using Monte Carlo simulation combined with pharmacokinetics/pharmacodynamics/ (PK/PD).

Methods

The minimum inhibitory concentration (MIC) of antibiotics against clinical isolates from 2013 to 2020 in Nanjing, China, was determined by agar dilution method. The probability of target attainment (PTA) was estimated at each MIC value and the cumulative fraction of response (CFR) was calculated to evaluate the efficacy of these regimens.

Results

All dosage regimens of seven antibiotics achieved PTAs ≥ 90% for MIC ≤ 0.06 µg/ml. But when the MIC was increased to 1 µg/ml, PTAs at each MIC value exceeded 90% only for ceftriaxone 1,000 mg and 2,000 mg, zoliflodacin 2,000 mg and 3,000 mg. Among them, the CFR values of each dosing regimen against N. gonorrhoeae only for ceftriaxone, cefixime and zoliflodacin were ≥ 90% in Nanjing from 2013 to 2020.

Conclusions

Cephalosporins are still the first-line drugs in the treatment of gonorrhea. However, the elevated MIC values of cephalosporins can lead to decline in clinical efficacy of the conventional dose regimens, and increasing the dose of ceftriaxone to 1,000 mg-2,000 mg may improve the efficacy. In addition, zoliflodacin is possible to be a potential therapeutic agent in the future.
Literature
2.
go back to reference Lin EY, Adamson PC, Klausner JD. Epidemiology, treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: current strategies and future directions. Drugs. 2021;81(10):1153–69.CrossRefPubMedPubMedCentral Lin EY, Adamson PC, Klausner JD. Epidemiology, treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: current strategies and future directions. Drugs. 2021;81(10):1153–69.CrossRefPubMedPubMedCentral
3.
go back to reference Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted Infections Treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.CrossRefPubMedPubMedCentral Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted Infections Treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.CrossRefPubMedPubMedCentral
4.
go back to reference Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;2020. 956462420949126. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;2020. 956462420949126.
5.
go back to reference Guidelines for diagnosis. And treatment of Syphilis, gonorrhea and genital Chlamydia trachomatis Infection. Chin J Dermatology. 2020;53(3):168–79. Guidelines for diagnosis. And treatment of Syphilis, gonorrhea and genital Chlamydia trachomatis Infection. Chin J Dermatology. 2020;53(3):168–79.
7.
go back to reference Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the Treatment of Neisseria gonorrheae, including Multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332–45.CrossRefPubMed Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the Treatment of Neisseria gonorrheae, including Multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332–45.CrossRefPubMed
8.
go back to reference Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73(8):2072–7.CrossRefPubMedPubMedCentral Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018;73(8):2072–7.CrossRefPubMedPubMedCentral
9.
go back to reference Trang M, Dudley MN, Bhavnani SM. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol. 2017;36:107–13.CrossRefPubMed Trang M, Dudley MN, Bhavnani SM. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol. 2017;36:107–13.CrossRefPubMed
10.
go back to reference Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22(11):982–92. quiz 993 – 985.CrossRefPubMed Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22(11):982–92. quiz 993 – 985.CrossRefPubMed
11.
go back to reference Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O’Donnell J, Unemo M, Van Bambeke F, et al. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic Drugs for uncomplicated gonorrhoea-challenges and opportunities. Clin Microbiol Infect. 2020;26(12):1630–5.CrossRefPubMed Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O’Donnell J, Unemo M, Van Bambeke F, et al. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic Drugs for uncomplicated gonorrhoea-challenges and opportunities. Clin Microbiol Infect. 2020;26(12):1630–5.CrossRefPubMed
12.
go back to reference Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J, Zhan S. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021;21(6):847–57.CrossRefPubMed Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J, Zhan S. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021;21(6):847–57.CrossRefPubMed
13.
go back to reference Wang F, Liu JW, Li YZ, Zhang LJ, Huang J, Chen XS, Chen SC, Yin YP. Surveillance and molecular epidemiology of Neisseria gonorrhoeae isolates in Shenzhen, China, 2010–2017. J Glob Antimicrob Resist. 2020;23:269–74.CrossRefPubMed Wang F, Liu JW, Li YZ, Zhang LJ, Huang J, Chen XS, Chen SC, Yin YP. Surveillance and molecular epidemiology of Neisseria gonorrhoeae isolates in Shenzhen, China, 2010–2017. J Glob Antimicrob Resist. 2020;23:269–74.CrossRefPubMed
14.
go back to reference Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP, Rice PA. Susceptibility trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical isolates in Nanjing, China, 2014 to 2018. Antimicrob Agents Chemother 2021, 65(3). Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP, Rice PA. Susceptibility trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical isolates in Nanjing, China, 2014 to 2018. Antimicrob Agents Chemother 2021, 65(3).
15.
go back to reference Qin X, Zhao Y, Chen W, Wu X, Tang S, Li G, Yuqi Y, Cao W, Liu X, Huang J, et al. Changing antimicrobial susceptibility and molecular characterisation of Neisseria gonorrhoeae isolates in Guangdong, China: in a background of rapidly rising epidemic. Int J Antimicrob Agents. 2019;54(6):757–65.CrossRefPubMedPubMedCentral Qin X, Zhao Y, Chen W, Wu X, Tang S, Li G, Yuqi Y, Cao W, Liu X, Huang J, et al. Changing antimicrobial susceptibility and molecular characterisation of Neisseria gonorrhoeae isolates in Guangdong, China: in a background of rapidly rising epidemic. Int J Antimicrob Agents. 2019;54(6):757–65.CrossRefPubMedPubMedCentral
16.
go back to reference Centers for Disease C, Prevention. Update to CDC’s Sexually Transmitted Diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal Infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–4. Centers for Disease C, Prevention. Update to CDC’s Sexually Transmitted Diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal Infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–4.
17.
go back to reference St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P. Update to CDC’s treatment guidelines for gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911–6.CrossRefPubMedPubMedCentral St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P. Update to CDC’s treatment guidelines for gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911–6.CrossRefPubMedPubMedCentral
18.
go back to reference Guan MQ, Yao L, Zhen Y, Song Y, Cui Y, Li SS. Melanin of Sporothrix globosa affects the function of THP-1 macrophages and modulates the expression of TLR2 and TLR4. Microb Pathog. 2021;159:105158.CrossRefPubMed Guan MQ, Yao L, Zhen Y, Song Y, Cui Y, Li SS. Melanin of Sporothrix globosa affects the function of THP-1 macrophages and modulates the expression of TLR2 and TLR4. Microb Pathog. 2021;159:105158.CrossRefPubMed
19.
go back to reference Yan J, Xue J, Chen Y, Chen S, Wang Q, Zhang C, Wu S, Lv H, Yu Y, van der Veen S. Increasing prevalence of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015-17). J Antimicrob Chemother. 2019;74(1):29–37.PubMed Yan J, Xue J, Chen Y, Chen S, Wang Q, Zhang C, Wu S, Lv H, Yu Y, van der Veen S. Increasing prevalence of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015-17). J Antimicrob Chemother. 2019;74(1):29–37.PubMed
20.
go back to reference Zhu B, Hu Y, Zhou X, Liu K, Wen W, Hu Y. Retrospective analysis of drug sensitivity of Neisseria gonorrhoeae in Teaching hospitals of South China. Infect Drug Resist. 2021;14:2087–90.CrossRefPubMedPubMedCentral Zhu B, Hu Y, Zhou X, Liu K, Wen W, Hu Y. Retrospective analysis of drug sensitivity of Neisseria gonorrhoeae in Teaching hospitals of South China. Infect Drug Resist. 2021;14:2087–90.CrossRefPubMedPubMedCentral
21.
go back to reference Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141–8.CrossRefPubMed Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141–8.CrossRefPubMed
22.
go back to reference Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of Infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4–15.CrossRefPubMed Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of Infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4–15.CrossRefPubMed
23.
go back to reference Wang Q, Liu Q, Xu J. Guidelines for Clinical Diagnosis, Treatment and Prevention of Sexually Transmitted Diseases (Second Edition). Shanghai scientific & technical pushishers 2020. Wang Q, Liu Q, Xu J. Guidelines for Clinical Diagnosis, Treatment and Prevention of Sexually Transmitted Diseases (Second Edition). Shanghai scientific & technical pushishers 2020.
24.
go back to reference Hoffken G, Barth J, Rubinstein E, Beckmann H. Group HAPs: a randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired Pneumonia. Infection. 2007;35(6):414–20.CrossRefPubMed Hoffken G, Barth J, Rubinstein E, Beckmann H. Group HAPs: a randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired Pneumonia. Infection. 2007;35(6):414–20.CrossRefPubMed
25.
go back to reference Zhao Y, Le W, Genco CA, Rice PA, Su X: Increase in Multidrug Resistant Neisseria gonorrhoeae FC428-Like Isolates Harboring the Mosaic penA 60.001 Gene, in Nanjing, China (2017-2020). Infect Drug Resist 2023, 16:4053-64.CrossRefPubMedPubMedCentral Zhao Y, Le W, Genco CA, Rice PA, Su X: Increase in Multidrug Resistant Neisseria gonorrhoeae FC428-Like Isolates Harboring the Mosaic penA 60.001 Gene, in Nanjing, China (2017-2020). Infect Drug Resist 2023, 16:4053-64.CrossRefPubMedPubMedCentral
26.
go back to reference Yan J, Chen Y, Yang F, Ling X, Jiang S, Zhao F, Yu Y, van der Veen S. High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J Antimicrob Chemother. 2021;76(4):936–9.CrossRefPubMed Yan J, Chen Y, Yang F, Ling X, Jiang S, Zhao F, Yu Y, van der Veen S. High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J Antimicrob Chemother. 2021;76(4):936–9.CrossRefPubMed
27.
go back to reference Barbee LA, Nayak SU, Blumer JL, O’Riordan MA, Gray W, Zenilman JM, Golden MR, Griffiss JM. A phase 1 Pharmacokinetic and Safety Study of Extended-Duration, high-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx. Sex Transm Dis. 2018;45(10):677–83.CrossRefPubMed Barbee LA, Nayak SU, Blumer JL, O’Riordan MA, Gray W, Zenilman JM, Golden MR, Griffiss JM. A phase 1 Pharmacokinetic and Safety Study of Extended-Duration, high-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx. Sex Transm Dis. 2018;45(10):677–83.CrossRefPubMed
28.
go back to reference Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015;59(1):467–74.CrossRefPubMed Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015;59(1):467–74.CrossRefPubMed
29.
go back to reference Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, et al. Single-Dose Zoliflodacin (ETX0914) for treatment of urogenital Gonorrhea. N Engl J Med. 2018;379(19):1835–45.CrossRefPubMed Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, et al. Single-Dose Zoliflodacin (ETX0914) for treatment of urogenital Gonorrhea. N Engl J Med. 2018;379(19):1835–45.CrossRefPubMed
30.
go back to reference Soda M, Ito S, Matsumaru N, Nakamura S, Nagase I, Takahashi H, Ohno Y, Yasuda M, Yamamoto M, Tsukamoto K et al. Evaluation of the Microbiological Efficacy of a single 2-Gram dose of extended-release azithromycin by Population Pharmacokinetics and Simulation in Japanese patients with Gonococcal Urethritis. Antimicrob Agents Chemother 2018, 62(1). Soda M, Ito S, Matsumaru N, Nakamura S, Nagase I, Takahashi H, Ohno Y, Yasuda M, Yamamoto M, Tsukamoto K et al. Evaluation of the Microbiological Efficacy of a single 2-Gram dose of extended-release azithromycin by Population Pharmacokinetics and Simulation in Japanese patients with Gonococcal Urethritis. Antimicrob Agents Chemother 2018, 62(1).
31.
go back to reference Smith PW, Zuccotto F, Bates RH, Martinez-Martinez MS, Read KD, Peet C, Epemolu O. Pharmacokinetics of beta-lactam antibiotics: clues from the past to help Discover Long-acting oral Drugs in the future. ACS Infect Dis. 2018;4(10):1439–47.CrossRefPubMedPubMedCentral Smith PW, Zuccotto F, Bates RH, Martinez-Martinez MS, Read KD, Peet C, Epemolu O. Pharmacokinetics of beta-lactam antibiotics: clues from the past to help Discover Long-acting oral Drugs in the future. ACS Infect Dis. 2018;4(10):1439–47.CrossRefPubMedPubMedCentral
33.
go back to reference Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36(5):993–6.CrossRefPubMedPubMedCentral Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36(5):993–6.CrossRefPubMedPubMedCentral
Metadata
Title
Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
Authors
Jiaojiao Zhong
Wenjing Le
Xuechun Li
Xiaohong Su
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08938-x

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine